The estimated Net Worth of Wayne Foster is at least 122 千$ dollars as of 31 January 2024. Mr Foster owns over 33,334 units of Atea Pharmaceuticals stock worth over 122,336$ and over the last 7 years he sold AVIR stock worth over 0$.
Mr has made over 2 trades of the Atea Pharmaceuticals stock since 2018, according to the Form 4 filled with the SEC. Most recently he exercised 33,334 units of AVIR stock worth 122,336$ on 31 January 2024.
The largest trade he's ever made was exercising 33,334 units of Atea Pharmaceuticals stock on 31 January 2024 worth over 122,336$. On average, Mr trades about 6,005 units every 274 days since 2018. As of 31 January 2024 he still owns at least 33,334 units of Atea Pharmaceuticals stock.
You can see the complete history of Mr Foster stock trades at the bottom of the page.
Wayne Foster CPA, CPA is the Sr. VP of Fin. & Admin. at Atea Pharmaceuticals.
Mr CPA is 52, he's been the Sr. VP of Fin. & Admin. of Atea Pharmaceuticals since . There are 7 older and no younger executives at Atea Pharmaceuticals. The oldest executive at Atea Pharmaceuticals, Inc. is Dr. Jean-Pierre Sommadossi Ph.D., 65, who is the Founder, Chairman, CEO & Pres.
Wayne's mailing address filed with the SEC is 225 FRANKLIN STREET, SUITE 2100, BOSTON, MA, 02110.
Over the last 4 years, insiders at Atea Pharmaceuticals have traded over 279,832$ worth of Atea Pharmaceuticals stock and bought 553,666 units worth 13,102,824$ . The most active insiders traders include Andrew A. F. Hack、Franklin M Berger、Springs Capital Management .... On average, Atea Pharmaceuticals executives and independent directors trade stock every 70 days with the average trade being worth of 229,012$. The most recent stock trade was executed by Bruce Polsky on 20 June 2024, trading 17,544 units of AVIR stock currently worth 61,229$.
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The company also develops AT-752, an oral purine nucleoside prodrug product candidate, which has completed Phase Ia clinical trial for the treatment of dengue; AT-777, an NS5A inhibitor; AT-787, a co-formulated, oral, pan-genotypic fixed dose combination of AT-527 and AT-777 for the treatment of hepatitis C virous (HCV); and AT-281, a pharmaceutically acceptable salt for the treatment or prevention of an RNA viral infection, including dengue fever, yellow fever, Zika virus, and coronaviridae viral infection, as well as Ruzasvir, an investigational oral, pan genotypic NS5A inhibitor for the treatment of chronic HCV infection. It has a license agreement with Merck & Co, Inc. for development and commercialization of ruzasvir for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.
Atea Pharmaceuticals executives and other stock owners filed with the SEC include: